Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Sandostatin

(Octreotide Acetate)

Phase 3Small molecule

Octreotide is used to control symptoms of certain hormone-producing tumors and to reduce fluid loss in patients with severe diarrhea. It works by mimicking a natural body hormone that slows down the release of other hormones and reduces intestinal movement.[1] Sandostatin is currently being investigated across 21 indications[3], with its most advanced program in Phase 3.[1]

Sandostatin is one of 454 small molecule programs targeting Insulin resistance. It is currently in Phase 3.

21

Indications

31

Total Trials

2

Active Trials

453

Competitors

Pipeline

Status by Indication[3][1]

Indication

Insulin ResistanceActive, not recruiting

AscitesActive, not recruiting

MetastasisUnknown

Liver TransplantActive, not recruiting

Thymus NeoplasmActive, not recruiting

LymphomaActive, not recruiting

ThymomaActive, not recruiting

Pancreatic Neuroendocrine TumorActive, not recruiting

Neuroendocrine CarcinomaActive, not recruiting

Liver CancerActive, not recruiting

Insulin ResistancePhase 1

Active, not recruiting

AscitesPhase 3

Active, not recruiting

MetastasisPreclinical

Unknown

Liver TransplantPhase 2

Active, not recruiting

Thymus NeoplasmPhase 2

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

ThymomaPhase 2

Active, not recruiting

Pancreatic Neuroendocrine TumorPhase 2

Active, not recruiting

Neuroendocrine CarcinomaPhase 1

Active, not recruiting

Liver CancerPhase 2

Active, not recruiting

Showing 10 of 20 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Sandostatin

Zolymbus

Adenocard

MS Contin

HHikma Pharmaceuticals LLC

Spravato

Sporanox

SSebela Pharmaceuticals Development LLC

Vfend

PPrism Pharmaceuticals

Perflutren Lipid Microsphere

IImaRx Therapeutics

Diuretic

RReprieve Cardiovascular, Inc

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Neuroendocrine Tumor

NCT00569127

Q1 2029

Phase 1Not yet recruiting

Insulin Resistance

NCT06558422

Clinical

Trials by Indication[1]

Diarrhea4 trials

Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT00075868·233 enrolled

Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00033605·130 enrolled

Fecal Calprotectin Levels in Mycophenolate Mofetil Induced Diarrhea and Treatment With Octreotide

Unknown status·UUniversity Health Network, Toronto··NCT02977897·10 enrolled

Show 1 more trial

Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer

Terminated· Novartis logo

Novartis·Phase 3·NCT00006269·89 enrolled

Acromegaly3 trials

Open Label Study of Octreotide Implant in Patients With Acromegaly

Completed· Endo Pharmaceuticals logo

Endo Pharmaceuticals·Phase 2·NCT00913055·34 enrolled

Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas

Terminated· Novartis logo

Novartis·Phase 4·NCT00242541·50 enrolled

Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly

Completed· Novartis logo

Novartis·Phase 3·NCT00372697·28 enrolled

Neuroendocrine Tumors2 trials

Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

Terminated·VVanderbilt-Ingram Cancer Center·Phase 2·NCT00466856·10 enrolled

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Withdrawn·EEastern Cooperative Oncology Group·Phase 2·NCT00227773

Gastrointestinal1 trial

Gastrointestinal Nutrient Transit and Enteroendocrine Function After Upper Gastrointestinal Surgery

Completed·SSt. James's Hospital, Ireland··NCT03734627·40 enrolled

Liver Cancer1 trial

Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT00257426·31 enrolled

20 more indications

Colorectal Cancer1 trial

Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00003057·500 enrolled

Neuroendocrine Tumor1 trial

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT00569127·427 enrolled

Insulin resistance1 trial

Human Models of Selective Insulin Resistance: Pancreatic Clamp

Not yet recruiting·—·Phase 1·NCT06558422·36 enrolled

Pancreatic1 trial

Pancreatic Clamp in NAFLD

Completed·—·Phase 1·NCT05724134·18 enrolled

Ascites1 trial

Octreotide in Treating Patients With Cancer-Related Malignant Ascites

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00182754·33 enrolled

Dexamethasone1 trial

Dexamethasone/Pancreatic Clamp P&F

Withdrawn·—·Phase 1·NCT06126354

Lymphoma1 trial

Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00002779·34 enrolled

Metastatic Neuroendocrine Tumor1 trial

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Completed·RRoswell Park Cancer Institute·Phase 1·NCT03879694·19 enrolled

Advanced Cancer1 trial

Octreotide and Doxorubicin in Treating Patients With Advanced Cancer

Completed·UUniversity of Pittsburgh·Phase 1·NCT00008073

Pancreatic Neuroendocrine Tumor1 trial

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01229943·150 enrolled

Prostate Cancer1 trial

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

Terminated·UUniversity of Southern California·Phase 2·NCT01469338·9 enrolled

Neuroendocrine Carcinoma1 trial

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01204476·27 enrolled

Breast Cancer1 trial

Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00002864·667 enrolled

Liver Transplant1 trial

A Feasibility Study of Octreotide Infusion During Liver Transplant.

Unknown status·UUniversity College, London·Phase 2·NCT04941911·30 enrolled

Thymoma1 trial

Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00003283·38 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients

Completed·AAmbrilia Biopharma, Inc.·Phase 3·NCT00616551·65 enrolled

Adult1 trial

Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers

Completed·DDauntless Pharmaceuticals·Phase 1·NCT03031535·32 enrolled

Interaction1 trial

Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects

Completed·LLexicon Pharmaceuticals·Phase 1·NCT02195635·24 enrolled

Surgery1 trial

Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery

Completed·NNorthwestern University·Phase 2·NCT00004895

Unspecified1 trial

Octreotide LAR in the Induction of Immunologic Response in NENs Patients

Completed·NNational Cancer Institute, Naples·Phase 2·NCT04129255·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 31 trial records for Octreotide Acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Octreotide Acetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Octreotide Acetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Somatostatin Receptor Agonist[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novartis

Related News